Private Eye

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

CEO, CFO, others buying at Critical Outcome (V:COT)

Updated Monday Sep 25, 2017 02:52 AM EDT

John C. Drake, a Senior Officer and 10% Holder, acquired 86,207 Common Shares at a price of $1.160 and 86,207 Warrants exercisable at $1.210 for a period of 12 months on a direct ownership basis through a prospectus or prospectus exempt offering on September 19th, 2017. This represents a $100,000 investment into the company's shares and an account share holdings change of 25.7%.

Under the same terms:

Alison Silva, CEO and Director, acquired 43,100 Common Shares and 43,100 Warrants on a direct ownership basis through a prospectus or prospectus exempt offering on September 19th, 2017. This represents a $49,996 investment into the company's shares and an account share holdings change of greater than 100%.

Douglas Stewart Alexander, a Director, acquired 13,000 Common Shares and 13,000 Warrants on a direct ownership basis through a prospectus or prospectus exempt offering on September 19th, 2017. This represents a $15,080 investment into the company's shares and an account share holdings change of 78.1%.

Eugene Francis Kelly, CFO, acquired 8,600 Common Shares and 8,600 Warrants on a direct ownership basis through a prospectus or prospectus exempt offering on September 19th, 2017. This represents a $9,976 investment into the company's shares and an account share holdings change of 34.5%.

Bruno Maruzzo, a Director, acquired 4,400 Common Shares and 4,400 Warrants on a direct ownership basis through a prospectus or prospectus exempt offering on September 19th, 2017. This represents a $5,104 investment into the company's shares and an account share holdings change of 16.1%.

Heung-Joon (John) Yoo, a Director, acquired 4,400 Common Shares and 4,400 Warrants on a direct ownership basis through a prospectus or prospectus exempt offering on September 19th, 2017. This represents a $5,104 investment into the company's shares and an account share holdings change of 73.7%.

Critical Outcome is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Critical Outcome Technologies Inc. (COTI) is a clinical-stage biopharmaceutical company. The Company is engaged in drug discovery and development. The Company uses machine learning to develop targeted therapies thereby managing the timeline and cost of getting new drug therapies to market. The Company's artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds with a high probability of being developed from disease specific drug discovery through chemical optimization and preclinical testing. The CHEMSAS platform technology is designed for small molecules, and as a drug candidate discovery engine can be applied to any disease target with information for the target of interest. The Company's initial focus is in advancing the treatment of cancer with the Company's lead compound, COTI-2, having a p53-dependent mechanism of action demonstrating selective and potent anti- cancer activity.

INK Edge Outlook

CONDITIONS:
Latest
6 months ago
1 year ago
Overall
N/A
N/A
N/A
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at inkresearch.com.
Two-week free trial for first time users.
Go to Cotinga Pharmaceuticals Inc. (COT)'s company page

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Comment On!

No Comments

Twitter

Search (past week) for $COT.CA

  • No tweets found

Stocktwits

Cotinga Pharmaceuticals Inc.

  • Symbol not found.